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Monoclonal antibody LB-2 to a surface antigen on human B cells, lymphoblast, monocytes and vascular 
endothelial cells largely inhibited adhesion among Epstein Barr virus-immortalized normal B cells (EBV-B) 
and concanavalin A-stimulated blood mononuclear cells (Con A-BMC) before and after phorbol ester treat- 
ment. The antibody inhibited to a lesser extent phorbol ester-induced aggregation of monocytes, U937 cells 
and fresh BMC and had virtually no inhibitory effect on the adhesion among enriched T cells and granulo- 
cytes. A surface glycoprotein band of 84 kDa was obtained from EBV-B cells by immunoprecipitation and 
gel electrophoresis. Immunological and biochemical studies clearly distinguished this molecule from gp90 
and associated glycoproteins which also mediate leukocyte adhesion. 
LB-2 antibody; Leukocyte antigen; Adhesion molecule 
1. INTRODUCTION 
Mononuclear leukocytes interact with each other 
and with vascular endothelium to generate immune 
and inflammatory responses. Some of these in- 
teractions are known to require cell-cell adhesion 
UA. 
mon antigen [5] almost completely inhibits phor- 
bol ester-induced adhesion among blood 
mononuclear cells (BMC), granulocytes and EBV- 
immortalized normal B cells (EBV-B) [6-81. This 
antibo.dy binds to gp90, a leukocyte surface 
glycoprotein which is non-covalently associated to 
gp160, gp155 and gp130 [4,9]. 
Phorbol esters, such as tetradecanoyl phorbol Another antigen weakly expressed on ‘resting’ B 
acetate (TPA) and phorbol dibutyrate (P(Bu)$, in- cells and monocytes but strongly displayed on ac- 
duce and enhance leukocyte adhesion and aggrega- tivated B cells and T cells is recognized by 
tion [3]. The intercellular binding is an energy- and monoclonal antibody LB-2, previously named 
temperature-dependent process that requires cell BB-2 [ 10,111. Here, this antibody allowed the iden- 
surface structures. Some of these adhesion tification of a novel adhesion molecule in EBV-B 
molecules appear to constitute ligands forming cells and concanavalin A (Con A)-stimulated 
adhesive cell-cell bonds referred to as CAMS (cell- blood mononuclear cells and was also found to 
adhesion molecules) [4]. react with vascular endothelial cells. 
Monoclonal antibody 60.3 to a leukocyte com- 
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2. MATERIALS AND METHODS 
2.1. Cells 
Unless otherwise stated the lymphoblastoid cell 
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line PSB-1 was used as source of EBV-B cells. 
Other cell lines used in this study have been 
described in [ll]. The SKW-3 cell line, derived 
from a T cell leukemia, was kindly provided by 
Professor Hans Wigzell. Blood mononuclear cells, 
a T cell-enriched population, and granulocytes 
were separated as in [6,7]. Monocytes were ob- 
tained from blood mononuclear cells by adherence 
to plastic dishes and this cell preparation contained 
99% OKMl positive cells and less than 2% T cells 
(T3 positive). Activated blood mononuclear cells 
were obtained by incubation with Con A (Sigma, 
St. Louis, MO) at 5 pg/ml for 3 days. Before use, 
these cells were extensively washed with 100 mM 
cu-methyl-D-mannoside (Sigma) to remove any 
residual lectin. Vascular endothelial cells were 
prepared from human umbilical veins and cultured 
as in [12]. 
2.2. Monoclonal antibodies 
Antibodies LB-2 (previously named BB-2) and 
60.3 were produced as previously reported 
[5,10,11]. Antibody W6/32 to class I transplanta- 
tion antigen was purchased from Sera-Lab (Lon- 
don, England). The three antibodies are murine 
IgGza and were used as ascites (LB-2 and W6/32, 
Ig content > 2 mg/ml) or purified Ig (60.3). OKMl 
and anti-T3 antibodies were obtained from Ortho 
Diagnostic Systems (Raritan, NJ) and New 
England Nuclear (Boston, MA), respectively. In- 
direct immunofluorescence studies were performed 
as in [8]. 
2.3. Measurement of cell aggregation 
After extensive washing, cells were resuspended 
at 5 x lo6 (cell lines) or 10 x lo6 (fresh blood cells) 
cells/ml in RPM1 1640 medium (Grand Island, 
NY) with 0.5% human albumin (KabiVitrum, 
Stockholm). Cell suspensions were spun at 
100 rpm at 37°C and treated with 60 nM P(Bu)2 
(Sigma) for 20 min. Cell aggregation and the effect 
of antibodies (at approx. 20rg/ml, unless other- 
wise stated) were measured microscopically as 
reported [6-81. 
2.4. Cell surface labelling, immunoprecipitation 
and gel electrophoresis 
EBV-B cells were surface-labelled with 3H after 
periodate oxidation and NaB3H4 reduction [13]. 
Immunoprecipitation was performed using rabbit 
128 
anti-mouse IgG (Dakopatts, Copenhagen) in the 
second step [14]. Polyacrylamide slab gel elec- 
trophoresis in the presence of SDS was done ac- 
cording to Laemmli [ 151 using 8% acrylamide gels. 
The 3H-labelled gels were treated for fluorography 
according to Bonner and Laskey [16]. 14C-labelled 
standard proteins were obtained from the 
Radiochemical Centre (Amersham, England). 
3. RESULTS 
Antibody LB-2 inhibited phorbol ester- 
enhanced aggregation of EBV-B cell (72%) in a 
concentration-dependent manner (fig. 1). At 
20pg/ml, the antibody blocked the cell aggrega- 
tion in more than 70%. Half inhibition was ob- 
tained with approx. 50 ng/ml. The spontaneous 
cell aggregation (22%) was also largely blocked by 
both antibodies while the characteristic phorbol 
ester-induced morphological changes [8] were not 
affected (not shown). Antibody LB-2 inhibited in- 
tercellular adhesion in EBV-B cells from four dif- 
ferent lines which had been passaged in vitro for a 
few months up to several years (not shown). In 
contrast, antibody W6/32 as well as many other 
antibodies to cell-surface antigens did not inhibit 
cell-cell binding [4,8]. Antibody LB-2 also in- 
hibited to a large extent phorbol ester-enhanced 
adhesion among lectin-activated blood mono- 
nuclear cells while a minor inhibitory effect was 
obtained when monocytes, U937 cells or fresh 
100 
- 90 
4 80 
mAb concentration (pg/mO 
Fig.1. Effect of monoclonal antibodies LB-2 (o), 60.3 
(A) and W6/32 (0) on phorbol ester-enhanced 
aggregation of EBV-B cells. 
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Table 1 
Effect of monoclonal antibodies LB-2,60.3 and W6/32 on phorbol ester- 
induced adhesion among different leukocytes 
Leukocyte8 Per cent Per cent inhibition of cell 
cell aggregation by monoclonal 
aggregationb antibodiesC 
LB-2 60.3 W6/32 
EBV-B cells 
Con A-blood mononuclear 
cells 
Monocytes 
U937 cells 
Blood mononuclear cells 
Enriched T cells 
Granulocytes 
67 72d 92 -4 
60 73 90 -5 
12 32 98 1 
24 23 97 -15 
58 13 74 -3 
31 3 89 -5 
90 0 82 0 
a All cells were resuspended in RPM1 1640 medium with 0.5% human 
albumin at 5 x lo6 (cell lines) or 10 x lo6 (fresh blood cells) per ml 
b Leukocyte aggregation was measured by counting aggregated or single 
cells after 20 min treatment with 60 nM P(Bu)2 and rotation at 100 rpm 
at 37°C 
’ Approx. 20 pg/ml of antibodies was added to the cells before phorbol 
ester treatment 
d Mean of at least two experiments 
Table 2 
Reactivity of monoclonal antibodies LB-2 and 60.3 with different cell 
types 
Cells (type) Immuno~uorescence reactivity 
Blood mononuclear cells 42 t/-t 95 + +/+ + + 
Enriched T cells 23 f 98 ++/+++ 
Monocytes 90 + 98 ++I+++ 
Con A-blood mononucIear cells 64 +I+ +.+ 99 ++/+++ 
Granulocytes 13 + 99 ++I+++ 
Erythrocytes 0 0 
Vascular endothelial cells 99 ++/+++ 0 
PSB- 1 (EBV-B) 80 +/+++ 90 +/+++ 
Raji (Burkitt’s lymphoma-B) 96 +/+++ 41 -t 
Molt-4 (T leukemia) 97 +,3 +++ 96 +, 3 +++ 
SKW-3 (T leukemia) 82 -+, 18 + + 98 ++/+++ 
U937 (histiocytic lymphoma) 98 +/++ 70 +/+ + 
K562 (erythroleukemia) 85 I-+ 60* 
LB-2 60.3 
Percentage of positive cells and labelling intensity were measured in a 
fluorescence microscope: (rt ) very weak, (+ ) weak, ( + + ) intermediate 
and ( + + + ) strong 
129 
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blood mononuclear cells were used (table 1). In 
contrast to antibody 60.3, no significant effect was 
observed with the antibody on enriched T cells and 
granulocytes. 
As reported in [lO,ll], antibody LB-2 reacted 
weakly with some blood cells, particularly 
monocytes, while T cells, granulocytes and 
erythrocytes were virtually negative (table 2). After 
a 3 day stimulation of blood mononuclear cells 
with Con A, labelling with the antibody was 
stronger in a larger number of cells. The reactivity 
of the antibody with cells from T, B, 
myelomonocytic and erythroid lineages was con- 
firmed and in addition, the antibody was found to 
react strongly with cultured vascular endothelial 
cells and to have a different specificity from an- 
tibody 60.3 (table 2). 
Under reducing conditions, a surface glycopro- 
tein band of 84 kDa was obtained from EBV-B 
cells by immunoprecipitation with antibody LB-2 
and gel electrophoresis (fig.2C), while an apparent 
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Fig.2. Polyacrylamide slab gel electrophoresis patterns 
of 3H-labelled EBV-B cells. (A) “C-labelled standard 
proteins: M, myosin; PHt,, phosphorylase b; BSA, 
bovine serum albumin; OA, ovalbumin; CA, carbonic 
anhydrase; (B) pattern of surface-labelled EBV-B cells: 
CLA, common leukocyte antigen; GPlOO, major 
sialoglycoprotein; HLA-A, class I transplantation 
antigen heavy chain; HLA-D, class II transplantation 
antigen; (C) pattern obtained by precipitation with 
antibody LB-2 under reducing conditions: GP84, 
glycoprotein with apparent molecular mass of 84 kDa; 
(D) pattern obtained by precipitation with antibody 60.3 
under reducing conditions; (E) pattern with no 
monoclonal antibody; (F) pattern obtained by 
precipitation with antibody LB-2 and run under 
nonreducing conditions. 
molecular mass of 77 kDa was observed under 
non-reducing conditions (fig.2F). Some labelled 
material remained on the top of the gel indicating 
aggregation. This may occur between the gp84 
molecules or between these and other molecules 
like the monoclonal antibody present in the im- 
mune precipitate. Antibody 60.3 precipitated two 
major surface glycoproteins with apparent 
molecular masses of 90 and 160 kDa from the 
same cells (fig.2D), as previously reported [8]. 
4. DISCUSSION 
The inhibitory effect of antibody LB-2 on cell 
aggregation induced or enhanced by phorbol esters 
indicates the participation of gp84 in the in- 
tercellular adhesion. We have previously tested 
several hundred different monoclonal antibodies 
directed against human leukocyte surface 
glycoproteins, and with one exception (antibody 
60.3), no antibody inhibited cell adhesion. Fab 
fragments from 60.3 inhibited adhesion as well. 
Since the LB-2 antibody does not affect induction 
of morphological changes, this surface molecule is 
apparently not involved in stimulation of the cells 
by these compounds. Thus, it seems probable that 
gp84 is directly involved in the intercellular binding 
and it may constitute an adhesive ligand or CAM. 
It is also likely that gp84 interacts with a previously 
described adhesion molecule [6-81. Interestingly, 
inhibition of cell aggregation by antibody LB-2 
was less than that shown by antibody 60.3 and 
never complete, suggesting the participation of ad- 
ditional adhesion molecules. When tables 1 and 2 
are compared, the inhibitory effect of antibody 
LB-2 on cell aggregation correlates well with the 
expression of its antigen on the cells. Since the an- 
tigen expression increases after stimulation of the 
cells with lectins or EBV, gp84 seems to mediate 
adhesion mainly in ‘activated’ mononuclear 
leukocytes. Moreover, the strong reactivity of the 
antibody with vascular endothelial cells suggests 
that the antigen constitutes an adhesion molecule 
also in these cells. 
In contrast to antibody LB-2, antibody 60.3 in- 
hibits adhesion among all types of leukocytes 
tested thus far. The latter antibody recognizes 
gp90, which is separately and non-covalently 
associated to gp160, gp155 and gp130 identified by 
monoclonal antibodies anti TA-l/LFA-1, OKMI 
130 
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and anti-LeuM5, respectiveIy [4,17]. Ail members 
of this protein complex are distinct from gp84 in 
both structure and cell distribution. In addition, 
the genes coding for gp90 and gp84 have been 
assigned to chromosome 21 and 19, respectively 
[9,181. 
Slight changes in the electrophoretic mobility of 
the sialoglycoprotein recognized by antibody LB-2 
suggest he presence of intra-chain disulfide bonds. 
The small difference in molecular mass from that 
described in the original publications, p76 [lO,ll], 
may be due to technical reasons. 
Interestingly, cells which react with antibody 
LB-2, namely monocytes, B lymphoblast, U937, 
K562 and endotheliai cells, are known to exert an 
‘accessory function’ in T cell proliferation induced 
by lectins [19-211. gp84 may mediate adhesion in 
this cell-cell interaction as well as in antigen 
presentation by the former cells. Moreover, adhe- 
sion of endothelial cells to lymphocytes may allow 
recirculation and Iocalization of the latter cells in 
different lymphoid organs [2]. 
Recently, monoclonal antibody RRl/l was 
reported to define a novel cell surface molecule in- 
volved in phorbol ester-induced aggregation of 
EBV-B cells 1221. Although the structure and cell 
distribution of this molecule are similar to those of 
gp84, only an extensive and parallei comparison of 
the two antigens will determine their relationship. 
Adhesion of mononuclear leukocytes to each 
other and to vascular endothelial cells may allow 
proliferation and differentiation of the former 
cells and control of EBV-B cells in vivo [6,8]. On 
the other hand, abnormal adhesion may contribute 
to the deveiopment of leukemia and Iymphoma. 
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